Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-015 single-dose study in adults with hypercholesterolemia (Part 1)
ISRCTN14586191Phase 2Recruiting
- Sponsor
- BaseCure Therapeutics
- Start
- Oct 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, single-blind trial of BC-015 in hypercholesterolemia (5 arms), sponsored by BaseCure Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
BC-015
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on ISRCTN14586191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14586191.